Law360, New York (July 03, 2007) -- In a recent public announcement, Johnson & Johnson disclosed that it may have violated the Foreign Corrupt Practices Act and had reported potential violations to the Department of Justice and the Securities and Exchange Commission. Johnson & Johnson’s disclosure highlights the risks of FCPA violations for the medical device industry.
It also reflects a broader trend of increased FCPA enforcement, as do recent cases involving multimillion dollar fines....
